Menu Search
Equities

HUTCHMED (China) Ltd

H7T2:FRA

HUTCHMED (China) Ltd

Actions
  • Price (EUR)3.22
  • Today's Change-0.04 / -1.23%
  • Shares traded150.00
  • 1 Year change+2.55%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

  • Revenue in HKD (TTM)4.75bn
  • Net income in HKD-326.64m
  • Incorporated2000
  • Employees1.97k
  • Location
    HUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
  • Phone+852 21281188
  • Fax+852 21281778
  • Websitehttps://www.hutch-med.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.